ProQR Therapeutics (PRQR) Stock Price, News & Analysis

Company Overview

ProQR Therapeutics N.V. is a biotechnology company focused on developing RNA-based medicines for genetic diseases. The company’s research is centered on using RNA therapies to correct or modify disease-causing genetic information, with the goal of addressing conditions that may not be effectively treated through conventional drug-development approaches.

ProQR’s technology portfolio includes Axiomer, an RNA-editing platform designed to make precise changes to RNA inside cells. The company has also developed investigational therapies for inherited retinal diseases and other genetic disorders. Its programs have included treatments intended to restore or improve the production of functional proteins affected by genetic mutations, although these therapies remain investigational and are not broadly approved medicines.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR has conducted research and development activities across Europe and the United States. The company has pursued collaborations with larger pharmaceutical organizations, including a strategic research collaboration with Eli Lilly focused on applying ProQR’s RNA-editing technology to potential new medicines.

Key Stats

• Today's Range: $1.54 to $1.62
• 50-Day Range: $1.57 to $2.43
• 52-Week Range: $1.33 to $3.10
• Volume: 1.16 million shs
• Average Volume: 654,103 shs
• Market Capitalization: $165.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.60
• Consensus Rating: Moderate Buy

ProQR Therapeutics Stock Analysis - MarketRank™

ProQR Therapeutics scored higher than 74% of companies evaluated by MarketBeat, and ranked 158th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ProQR Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

ProQR Therapeutics has a consensus price target of $7.60, representing about 384.1% upside from its current price of $1.57.

Amount of Analyst Coverage

ProQR Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for ProQR Therapeutics are expected to decrease in the coming year, from ($0.45) to ($0.49) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ProQR Therapeutics is -3.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ProQR Therapeutics is -3.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ProQR Therapeutics has a P/B Ratio of 2.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.49% of the float of ProQR Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

ProQR Therapeutics has a short interest ratio ("days to cover") of 4.15.

Change versus previous month

Short interest in ProQR Therapeutics has recently decreased by 2.26%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ProQR Therapeutics does not currently pay a dividend.

Dividend Growth

ProQR Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: -0.36

News Sentiment

ProQR Therapeutics has a news sentiment score of -0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for ProQR Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for PRQR on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.

MarketBeat Follows

3 people have added ProQR Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 4.3 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of ProQR Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $519,000.00 in company stock, which represents 0.3138% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, ProQR Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $519,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

8.40% of the stock of ProQR Therapeutics is held by insiders.

Percentage Held by Institutions

32.65% of the stock of ProQR Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/09/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PRQR
• CIK: 1612940
• Web: www.proqr.com
• Phone: (188) 166-7000
• Fax: N/A
• Employees: 166
• Year Founded: 2012

Price Target and Rating

• Average Price Target for ProQR Therapeutics: $7.60
• High Price Target: $10.00
• Low Price Target: $3.00
• Potential Upside/Downside: +384.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$47.73 million
• Net Margins: -223.51%
• Pretax Margin: -229.40%
• Return on Equity: -73.83%
• Return on Assets: -35.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.49
• Quick Ratio: 3.49

Sales & Book Value

• Annual Sales: $18.36 million
• Price / Sales: 9.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.53 per share
• Price / Book: 2.96

Miscellaneous

• Outstanding Shares: 105,363,000
• Free Float: 96,513,000
• Market Cap: $165.42 million
• Optionable: Optionable
• Beta: 0.20